CCAT2 and breast cancer: In the presence of a specific inhibitor of the ERK/MAPK pathway (U0126), the expression of CCAT2 decreased significantly in the tamoxifen-resistant breast cancer cells compared to normal cells, which suggest that the ERK/MAPK pathway regulates the expression of CCAT2 (Figure 2).